ALT
failedAltimmune, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Altimmune's post-earnings gap on 4.4x volume signals that investors are likely responding to updates on pemvidutide, the company's GLP-1/glucagon dual agonist targeting both obesity and MASH (metabolic dysfunction-associated steatohepatitis). The obesity therapeutic market is one of the largest and fastest-growing in pharma, and any clinical, regulatory, or partnering milestones on pemvidutide could fundamentally alter the risk/reward profile for this micro-cap biotech. Even incremental de-risking — such as positive biomarker data, enrollment progress, or regulatory guidance — can cause sharp repricing given the binary nature of clinical-stage assets. The volume surge suggests institutional interest beyond routine retail flow. With ALT trading near its 50-day SMA and well off recent lows, the stock may be transitioning from a speculative oversold bounce to a more sustained accumulation phase if investors perceive improving probability of Phase 2/3 success or a strategic partnership. However, the failure to reclaim the 200-day SMA indicates sentiment has not fully inflected — this remains a show-me story where execution on clinical endpoints is paramount.
Analyzed by rerate-v2+glm-5.2 · Jul 31, 2026
Catalysts
- Pemvidutide clinical data readouts (efficacy, safety, or histology endpoints in obesity or MASH trials)
- Potential partnership or licensing deal with a larger pharma for pemvidutide commercialization rights
- Positive regulatory interactions with FDA including trial design alignment or Fast Track/Breakthrough designations
- Progress in MASH indication — a market with no currently approved FDA therapies, representing significant optionality
- Competitive differentiation from existing GLP-1 agents (Wegovy, Zepbound) on muscle preservation or tolerability
Risks
- Clinical trial failure or safety signals for pemvidutide would be catastrophic for the stock
- Cash runway and likely need for dilutive equity raise or unfavorable partnership terms given pre-revenue status
- Intense competition in obesity from well-capitalized incumbents (Novo Nordisk, Eli Lilly, Amgen, Pfizer)
- Regulatory delays or additional trial requirements from FDA
- Small biotech volatility — thin float and binary outcomes can cause violent swings in both directions
- No current revenue stream means the stock is entirely valued on future optionality
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $2.92 | $3.10 | $2.89 | 8.30M |
| Day 2 | $2.98 | $3.01 | $2.86 | 5.44M |
| Day 3 | $2.84 | $2.99 | $2.78 | 3.89M |
| Day 4 | $3.00 | $3.03 | $2.86 | 4.65M |
| 📍 Day 5 | $3.07 | $3.08 | $2.95 | 8.16M |
Signal Breakdown
Gap 100% filled — price gave back most of the post-earnings gap
Volume sustained — only 2% decline suggests continued accumulation
Mixed price trajectory — no clear trend
Moderate drawdown (7.0%)
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026